Chimeric antigen receptor (CAR)-T cell immunotherapies have revolutionized the treatment of hematopoietic cancers and spurred research in engineered immune effector cell therapy.
Novel immuno-oncology approaches take advantage of our powerful immune system by reprogramming immune cells (cytotoxic T cells, natural killer cells, or macrophages). So far, five approved CAR-T cell therapeutics target proteins CD19 and BCMA, both expressed in B lymphocytes. Many more clinical trials are ongoing, including trials that investigate new targets or novel approaches for the treatment of solid tumors.
This eBook will take a look at the tools and technologies available to accelerate research in immuno-oncology.